RISE-PD Full Data Highlight IPX203’s Impa... - Cure Parkinson's
RISE-PD Full Data Highlight IPX203’s Impact as Promising Parkinson Treatment

Written by

Farooqji
To view profiles and participate in discussions please or .
6 Replies
•
extended-release carbidopa-levodopa (CD/LD)
Indeed, it seems like old wine in new bottles. Moreover, the comparison with IR CD-LD is comparing apples with oranges. One would think that a comparison with ER CD-LD would make more sense, but of course the outcome would then be somewhat less spectacular. Yet the following study shows that when comparing with Rytary, there is indeed an interesting difference, because IPX203 has a significantly longer pharmacodynamic effect.
Worry is that cost will be high making insurers reluctant in the US and unavailable in UK. Only useful if available
Not what you're looking for?
You may also like...
IPX203 shows sustained safety, efficacy in RISE-PD extension trial
Using IPX203, an extended-release formulation of carbidopa/levodopa (CD/LD), was associated with a...
Clinical Stabilization in Parkinson´s Disease: The Multi-Target Treatment Description and Results
Here is an interesting article entitled,
Clinical Stabilization in Parkinson´s Disease: The...
Allopregnanolone as a Regenerative Treatment for Parkinson's Disease (Allo-PD)
I just happened upon this trial and it is something I had never heard of. It looks like a very...
Trehalose as a promising therapeutic candidate for the treatment of Parkinson's disease - 2019
Hats off to sunvox for having mentioned Trehalose a few times in these forums...
WHICH WOULD YOU CONSIDER AS THE MOST BENEFICIAL TO YOU AS A PD TREATMENT? MEDICATION OR DBS.
Hi fellow parkies and caregivers.For patients and caregivers,your opinions we go a long way to help...